Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 176   

Articles published

PFE 30.45 +0.01 (0.03%)
price chart
Why Pfizer Inc. (PFE) May Not Bid For AstraZeneca plc (ADR) (AZN) Again?
If investors thought Pfizer Inc. (NYSE:PFE) would still pursue AstraZeneca plc (ADR) (NYSE:AZN) deal then their hopes are up in the air.
Merck Collaboration Rules Out AstraZeneca Acquisition--For Now  Seeking Alpha
Healthcare Stocks in the Spotlight - Pfizer Inc. (NYSE:PFE), DaVita ...  Techsonian (press release)
Related articles »  
Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic ...
LOS ANGELES, Nov. 18, 2014 /PRNewswire/ -- Sanguine Biosciences - a biotechnology company focusing on technology development, patient engagement and study recruitment - will use its proprietary mobile application and direct-to-patient platform, ...
Related articles »  
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether.
Related articles »  
Pfizer to pay up to $2 billion for cancer alliance with Germany's Merck
Pfizer Inc. PFE looks like it has abandoned any hope of a merger with the U.K.'s Astrazeneca Plc AZN , after announcing a wide-ranging deal to cooperate on cancer drugs with Germany's Merck KgAA MERK .
Pfizer Cancer Pact With Merck Shows Waning Astra Pursuit  Bloomberg
Pfizer Buying Rights to Merck Cancer Drug  WKRB News
Related articles »  
Is Pfizer Spending Enough On R&D?
The company also stated in the 10-K that R&D spending may include upfront and milestone payments for intellectual property rights.
Related articles »  
Op-Ed: Pfizer Inc. is active, vital, taxpaying part of Eastern Connecticut
The Chamber of Commerce of Eastern Connecticut would like to set the record straight regarding Pfizer Inc.'s presence and future in southeastern Connecticut.
Related articles »  
Report: Pfizer 'Unlikely' To Pursue Acquisition Of AstraZeneca
A separate banker who is also familiar with Pfizer's strategy told Reuters that the company ´┐Żnever stopped looking at targets in Europe after the AstraZeneca debacle.
Related articles »  
Warren Buffett's Investing Strategy: Is Pfizer Inc. a Perfect Fit?
Yet, one company you won't currently find in Buffett and Berkshire's portfolio is the world's largest pharmaceutical company by revenue, Pfizer (NYSE: PFE ) . Today, we'll take a closer look at whether or not Pfizer would make a perfect fit for Warren ...
Related articles »  
3 Dividend Stocks Better Than Pfizer, Inc.
Pfizer (NYSE: PFE ) reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter.
Related articles »  
New Tax Rules Won't Stop Pfizer From Bidding U.S. Goodbye
Revenue for the third quarter fell 2 percent to $12.4 billion, Pfizer reported yesterday. Full-year sales will be as much as $49.7 billion this year, compared with a prior forecast of $50.7 billion, the company said. Profit excluding one-time items ...
Tax rule won't stop Pfizer from bidding goodbye  Salt Lake Tribune
Related articles »